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Use and preventive value of metformin in geriatric women with 
polycystic ovary syndrome                                                  
Objective: To establish the effects of long-term use and preven-
tive value of metformin in geriatric women with PCOS.
Methods: A search of published review articles was carried out 
in sites such as NCBI, ScienceDirect, Elsevier, Springer, Wolters 
Kluwer, among others, using the key words: “polycystic ovary 
syndrome”, “PCOS”, “Polycystic ovary syndrome and metformin”, 
“ effects of metformin and PCOS “,” insulin resistance and met-
formin “and” long-term sequelae of polycystic ovarian syndrome “.
Results: We retrospectively analyzed data specific to the ran-
domized clinical trial of Pedersen et al. 2017, to determine the im-
pact that treatment had for twelve months with metformin in three 
specific variables: weight, total cholesterol and HDL. The study 
was conducted in 40 Caucasian women from 18 to 39 years of 
age, with a fixed dose of metformin (2 g / day for 12 months), 
who met the Rotterdam criteria for PCOS in their genetic variant 
MATE1 with SOP7
Conclusions: It was confirmed that the establishment of twelve-
month treatment with metformin in the randomized clinical trial of 
Pedersen et al. 2017 had a significant effect on the three specific 
variables: weight, total cholesterol and HDL.
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INTRODUCTION 
Polycystic ovary syndrome (PCOS) is the most 
common endocrine disorder of women of 
reproductive age that affects 4 to 18% of women 
and is characterized by broader metabolic 
characteristics that include obesity, dyslipidemia 
and insulin resistance.1-5 The consensus of the 
European Society of Reproduction and Human 
Embryology / American Society of Reproductive 
Medicine (ESHRE / ASRM) established through 
the Rotterdam Criteria that at least two of the 
following characteristics are needed to make the 
diagnosis; Anovulation or oligoovulation with 
less than nine menstrual periods every 12 
months, symptoms or biochemical evidence of 
hyperandrogenism; and at least twelve small 
follicles from 2 to 9 mm in at least one 
ovarioechography.5-10 
It is estimated that insulin resistance plays a 
fundamental role in the pathogenesis of PCOS, 
since it leads to a compensatory increase in 
insulin production by pancreatic beta cells to 
control hyperglycemia, however, in the long term 
it leads to failure of this metabolic compensation 
and consequently to diabetes mellitus 2 (DM2). 
Likewise, hyperinsulinemia is considered to 
increase hyperandrogenism through a central 
role or by decreasing the circulating levels of sex 
hormone binding globulin. PCOS is not a simple 
reproductive disorder, but rather a condition that 
has long-term consequences and complications 
with a high impact on the morbidity and mortality 
of geriatric women. Pathologies such as type 2 
diabetes mellitus, metabolic syndrome, vascular 
brain disease, hypertension, coronary heart 
disease and endometrial cancer are the main 
long-term sequelae of PCOS, of which the 
majority have been attributed to obesity and 
resistance to insulin, although neither situation is 
diagnostic criteria for the syndrome. Therefore, 
treatment strategies should focus primarily on 
the proper management of insulin resistance 
and obesity. Obesity in women with PCOS has 
an increased prevalence of 2.8 times (50 to 
80%) compared to women who do not have the 
syndrome. In the original description of the 
syndrome by Stein and Leventhal in 1935, 60% 
were obese. Unfortunately, this condition, so 
common in women with PCOS, exacerbates the 
symptoms of the syndrome. The prophylactic 
use of metformin, an insilunisensitizing agent, in 
patients are PCOS, allows to reduce the risk of 
long-term sequelae, its pharmacological 
characteristics and efficacy will be described 
below. Metformin is a drug widely indicated in 
the treatment of type 2 diabetes, belonging to the 
group of biguanides, however, in addition to its 
use in patients with diabetes, its application has 
been widespread in women with PCOS. 9-11 In 
1980 the association between 
hyperandrogenism and hyperinsulinemia in 
PCOS was discovered thanks to Burghen et als. 
Since 1996 it has been known that the 
administration of this drug reduced insulin and 
androgen levels in women with PCOS and since 
this date there have been many subsequent 
studies confirming this action.4 
In the 1990s, metformin was shown to improve 
hyperandrogenism in obese and non-obese 
women with PCOS, this due to a reduction in 
hyperinsulinemia due to increased insulin 
sensitivity. In type 2 diabetes, the glycemic 
response to metformin is hereditary, although 
the genetic contribution is probably the result of 
individual variants throughout the genome rather 
than a few loci with large effect sizes. Similarly, 
genetic factors are likely to mediate the 
response to metformin in PCOS. Metformin 
works by improving the sensitivity of peripheral 
tissues to insulin, which results in a reduction in 
circulating insulin levels. Metformin inhibits 
hepatic gluconeogenesis and also increases 
glucose uptake in peripheral tissues and 
reduces oxidation of fatty acids.12-13 
The systemic benefits of metformin therapy for 
women with PCOS are widely recognized, but 
knowledge of the molecular mechanisms of its 
action and to what extent it beneficially affects 
uterine function is limited. The mechanism of 
action of metformin is not yet It is well known, but 
appears to have several functions.14 Metformin 
reduces insulin resistance, hepatic 
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gluconeogenesis and glucose uptake in the
intestine, thereby improving insulin secretion
from pancreatic β cells, thereby reducing
glucose in the blood. It was also shown that
metformin inhibits hepatic gluconeogenesis, by
modulating the 5'-adenosine monophosphate
activated protein kinase (AMPK), which depends
on the regulation of the orphan nuclear small
heterodimer receptor (SHP).2 Serine-threonine
protein kinase 11 (SK11) together with AMPK
signals are involved in the suppression of genes,
which encode gluconeogenic and lipogenic liver
enzymes in the hepatic pathway induced by
metformin.3 In other studies, its mechanism of
action is known to inhibit hepatic glucose
production and increase peripheral insulin
sensitivity to insulin, the latter effect is very
useful in non-diabetic women who have PCOS
and has demonstrated long-term improvement
of the menstrual cycle, ovulation,
hyperandrogenism and hirsutism.4 Skeletal
muscle accounts for more than 80% of the
glucose uptake stimulated by insulin. In insulin
resistant skeletal muscle cell cultures, metformin
was able to restore insulin signaling defects,
including reduction of insulin stimulated insulin
receptor and phosphorylation of IRS-1, as well
as phosphatidyl activity inositol 3-kinase (PI3K).7
It has been reported that chronic treatment with
metformin inhibits the accumulation of lipids in
human skeletal muscle and increases the
activity of atypical basal and insulin stimulated
protein kinase C (aPKC), without altering the
basal and insulin stimulated activation of the
PI3K dependent on IRS-1 and Akt (also known
as protein kinase B, PKB) 7,11. However, it was
shown that treatment with acute metformin
prevents insulin-induced suppression of
oxidation of fatty acids in oxidative muscles15.
Consequently, such lipid effects could contribute
to improving insulin sensitivity and insulin
stimulated glucose uptake.
Dyslipidemia is the most prevalent metabolic
aberration in PCOS, which is most frequently
represented by atherogenic dyslipidemia typical
of IR states, that is, hypertriglyceridemia,
decreased HDL cholesterol levels and increased 
small LDL cholesterol. and dense. Compared to 
healthy women, women with lean and obese 
PCOS had abnormal levels of 
phosphatidylcholine, free fatty acids and 
polyunsaturated fatty acids (PUFAs). In addition, 
oxidative stress in PCOS can participate in 
systemic inflammation and, together with IR and 
subsequent hyperinsulinemia, can influence the 
ovarian compartment and endothelial cells, 
resulting in hyperandrogenism, anovulation and 
CV disorders. It was shown that insulin and 
androgens may have opposite effects on lipid 
profiles in patients with PCOS9. Women with 
PCOS have an increased risk of cardiovascular 
disease as a result of the presence of insulin 
resistance and its related metabolic 
consequences, such as metabolic syndrome, 
type 2 diabetes and dyslipidemia, however, the 
actual prevalence of disease is unknown. 
cardiovascular in PCOS.12 
The main side effects associated with metformin 
treatment are gastrointestinal symptoms of 
nausea, diarrhea, flatulence, bloating, anorexia, 
metallic taste and abdominal pain. These 
symptoms occur with varying degrees in patients 
and in most cases they resolve spontaneously. 
The severity of side effects can be reduced by 
the gradual administration of metformin and the 
assessment of dose increase guided by the 
severity of symptoms. An initial dose of 500 mg 
per day during the main meal of the day for 1 to 
2 weeks may decrease side effects and allow 
tolerance to develop. A weekly or biweekly 
increase of 500 mg per day may be performed 
as necessary until a maximum dose of 2500 to 
2550 mg / day is reached, depending on the 
clinical benefit and side effects. If the increase in 
the dose causes a worsening of the effects. 
Slow-release metformin may be associated with 
fewer side effects. Metformin can also cause 
malabsorption of vitamin B12 in the distal ileum 
in approximately 10 to 30% of patients, which is 
an effect that depends on age, dose and 
duration of treatment Rarely, lactic acidosis can 
occur , mainly in diabetic patients, which is a 
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serious condition that can be life threatening.
However, unless there is a contraindication to
take metformin such as kidney disease, the risk
of lactic acidosis is negligible.11-16
METHODS
A quantitative systematic review of review
articles, original articles, experimental articles
and meta-analyzes published from 2010 to 2018
was carried out on sites such as NCBI,
ScienceDirect, Elsevier, Springer, Wolters
Kluwer among others, using the keywords:
"polycystic ovary syndrome", "PCOS",
"Polycystic ovary syndrome and metformin",
"effects of metformin and PCOS", "insulin
resistance and metformin" and "long-term 
sequelae of polycystic ovarian syndrome". 
RESULTS 
Specific data from the randomized clinical trial of 
Pedersen et al. 2017, to determine the impact 
that the treatment had during twelve months with 
metformin in three specific variables: weight, 
total cholesterol and HDL. The study was 
conducted in 40 Caucasian women 18 to 39 
years of age, with a fixed dose of metformin (2 g 
/ day for 12 months), who met the Rotterdam 
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The effects of 1 year of treatment with metformin 
in the first variable analyzed (weight) of 40 
patients with PCOS were: Pre-Treatment (79.9 ± 
0.51kg) and Post-Treatment (77.6 ± 1.86kg) 
(Figure 1). The statistical analysis of the weight 
of the 40 Pre-Treatment and Post-Treatment 
patients was carried out with the T-student 
parametric test using GraphPad Prism 5.0 
software and a value of p = 0.0001 was obtained. 
Likewise, the effects of 1 year of metformin 
treatment in the second analyzed variable (total 
cholesterol) of 40 patients with PCOS were: Pre-
Treatment (4.7 nmol / L) and Post-Treatment 
(4.78 ± 0.15 nmol / L) ( Figure 2). The statistical 
analysis of the total cholesterol of the 40 Pre-
Treatment and Post-Treatment patients was 
carried out with the T-student parametric test 
using GraphPad Prism 5.0 software and a value 
of p = 0.0015 was obtained. 
Finally, the effects of 1 year of metformin 
treatment on the third analyzed variable (HDL) 
of 40 patients with PCOS were: Pre-Treatment 
(1.5nmol / L) and Post-Treatment (1.58 ± 
0.05nmol / L) (Figure 3 ). The statistical analysis 
of the HDL of the 40 Pre-Treatment and Post-
Treatment patients was carried out with the T-
student parametric test using GraphPad Prism 
5.0 software and a value of p = 0.0001 was 
obtained. 
DISCUSSION 
It was determined through the statistical analysis 
performed in the 40 patients with PCOS that the 
treatment with metformin for one year had a high 
impact on the three variables (weight, total 
cholesterol and HDL). The result of the effect on 
weight was very highly significant, which allows 
us to infer that one of the main causes of long-
term sequelae in women with PCOS, obesity, 
can be controlled and even eliminated through 
the daily use of metformin and the sum of 
changes in the lifestyle of the patients. Likewise, 
the result of the effect on total cholesterol was 
highly significant, which means that total 
cholesterol may increase instead of decreasing 
in PCOS patients for two reasons, the first 
because in the analysis performed it was 
observed that the levels of DHL increased and 
this increase is inferred caused the increase in 
total cholesterol, and second is that it is essential 
to change the lifestyle of patients with diet and 
exercise to lower cholesterol levels despite the 
favorable increase that HDL favors. Finally, the 
result of the effect on HDL was very highly 
significant, since it increased after one year of 
treatment, which allows us to conclude that 
metformin treatment is directly involved in 
increasing the levels of “good cholesterol” in the 
blood, and is inferred This is the reason why total 
cholesterol levels increased. 
CONCLUSION 
IJOAR: http://escipub.com/international-journal-of-aging-research/                        6
Jazmín Abril Pérez Aguilar et al., IJOAR, 2019 2:53
It was determined that treatment for 12 months
with metformin the randomized clinical trial of
Pedersen et al. 2017 had a significant effect on
the three specific variables: weight, total
cholesterol and HDL. Therefore, it is concluded
that both lifestyle modifications, through the
improvement of diet and exercise that produces
weight loss, as well as metformin as a treatment
for PCOS, represent the cornerstone of the
effective improvement of Long-term health and
thus avoid subsequent sequelae in geriatric
women. The use of metformin in PCOS may
show different results in the different analyzes
since it depends largely on the variability of the
patients in the phenotypes and their metabolic
parameters, in the case of the analysis
presented, the evidence shows a broadly
positive effect, and despite not being evident
until now, it is inferred that the prophylactic use
of metformin would reduce the risk of disease
and sequelae of PCOS in the long term in these
patients. However, further studies must be
carried out to establish determining criteria.
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